The increased expression of CCL2, as well as Ly6C + CCR2+ monocyte levels, is also enhanced in response to the neoadjuvant treatment of breast cancer with taxanes and anthracyclines: they lead to the secretion of tEVs enriched in Annexin-A6, which can activate NF-kB-dependent endothelial cells in an Annexin-A6-dependent manner. The gene discussed is ANXA6; the disease is breast cancer.